19种药品纳入！首版商保创新药目录发布

Core Insights - The 2025 National Medical Insurance Drug List has successfully added 114 new drugs, with 50 being innovative drugs, achieving an overall success rate of 88%, an increase from 76% in 2024 [2] - The new drug lists will be implemented starting January 1, 2026, enhancing coverage for critical diseases and rare conditions [2] Group 1 - The 2025 National Medical Insurance Drug List includes drugs for major diseases such as triple-negative breast cancer, pancreatic cancer, and lung cancer, as well as treatments for rare diseases like Langerhans cell histiocytosis and thalassemia [2] - The total number of drugs in the National Medical Insurance Drug List has increased to 3,253, comprising 1,857 Western medicines and 1,396 traditional Chinese medicines, significantly improving coverage for key areas such as cancer, chronic diseases, and rare diseases [2] Group 2 - Since the establishment of the National Medical Insurance Bureau in 2018, the drug list management policies have been continuously improved, allowing for annual dynamic adjustments instead of the previous 4-8 year cycle [3] - The focus on clinical value and patient benefits has led to the inclusion of innovative therapies, such as immune therapies and antibody-drug conjugates, enhancing the quality of the drug list [5] Group 3 - A total of 949 drugs have been added to the list since 2017, representing a nearly 40% increase from the 2,535 drugs in the 2017 list, while 467 drugs have been removed, facilitating the update of clinical medications [5] - As of October 2025, negotiated drugs have benefited 1.08 billion insured patients, with fund expenditures reaching 465.55 billion yuan, driving drug sales of approximately 680 billion yuan [5]